Microtubule Active Agents: Beyond the Taxane Frontier

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Clinical Cancer Research

• Publication date

  2008-11-15

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1158/1078-0432.CCR-08-0169PMID 19010832
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase I clinical and pharmacokinetic study of 3-weekly, 3-h infusion of ixabepilone (BMS-247550), an epothilone B analog, in Japanese patients with refractory solid tumors

  2008cited by this paper
• Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes.

  2007cited by this paper
• Phase I clinical study of the novel epothilone B analogue BMS-310705 given on a weekly schedule.

  2007cited by this paper
• Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment.

  2007cited by this paper
• Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy.

  2007cited by this paper
• Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer.

  2007cited by this paper
• Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy.

  2007cited by this paper
• Phase I trial of KOS-1584 (a novel epothilone) using two weekly dosing schedules

  2007cited by this paper
• Phase II trial of the novel epothilone ZK-EPO in patients with platinum resistant ovarian cancer

  2007cited by this paper
• Adjuvant (adj) bevacizumab (B) plus dose-dense (dd) doxorubicin/cyclophosphamide (AC) followed by nanoparticle albumin- bound paclitaxel (nab-p) in early stage breast cancer (BC) patients (pts): Cardiac safety

  2007cited by this paper
• Cyclostreptin binds covalently to microtubule pores and lumenal taxoid binding sites.

  2007cited by this paper
• Activity of patupilone for the treatment of recurrent or progressive brain metastases in patients (pts) with non-small cell lung cancer (NSCLC): An open-label, multicenter, phase II study

  2007cited by this paper
• In vitro and in vivo anticancer activities of synthetic (-)-laulimalide, a marine natural product microtubule stabilizing agent.

  2007cited by this paper
• Peloruside A synergizes with other microtubule stabilizing agents in cultured cancer cell lines.

  2007cited by this paper
• Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel

  2007cited by this paper
• A phase 2 study of TZT-1027, administered weekly to patients with advanced non-small cell lung cancer following treatment with platinum-based chemotherapy.

  2007cited by this paper
• Phase II study of CT-2103 as first- or second-line chemotherapy in patients with metastatic breast cancer: unexpected incidence of hypersensitivity reactions

  2007cited by this paper
• Activity of second‐line chemotherapy in docetaxel‐refractory hormone‐refractory prostate cancer patients

  2007cited by this paper
• Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane®) on three treatment schedules in patients with solid tumors

  2007cited by this paper
• Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine.

  2007cited by this paper
• Phase II study of weekly nanoparticle paclitaxel (ABI-007), carboplatin and trastuzumab as first-line therapy of HER2-positive metastatic breast cancer.

  2006cited by this paper
• A retrospective evaluation of second‐line chemotherapy response in hormone‐refractory prostate carcinoma

  2006cited by this paper
• Total synthesis and antitumor activity of ZK-EPO: the first fully synthetic epothilone in clinical development.

  2006cited by this paper
• Phase II study of xyotax (PPX) for androgen independent prostate cancer (AIPC).

  2006cited by this paper
• A phase I trial of weekly combination KOS-862 (Epothilone D) and trastuzumab in HER-2 overexpressing malignancies.

  2006cited by this paper
• 2-Methoxyestradiol suppresses microtubule dynamics and arrests mitosis without depolymerizing microtubules

  2006cited by this paper
• A Phase II trial of epothilone B analogue BMS-247550 (NSC #710428) ixabepilone, in patients with advanced pancreas cancer: A Southwest Oncology Group study

  2006cited by this paper
• Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer.

  2006cited by this paper
• Synergistic Effects of Peloruside A and Laulimalide with Taxoid Site Drugs, but Not with Each Other, on Tubulin Assembly

  2006cited by this paper
• Effects of Patupilone (Epothilone B; EPO906), a Novel Chemotherapeutic Agent, in Hepatocellular Carcinoma: An in vitro Study

  2006cited by this paper
• Vinflunine – an active chemotherapy for treatment of advanced non-small-cell lung cancer previously treated with a platinum-based regimen: results of a phase II study

  2006cited by this paper
• Paclitaxel Poliglumex (PPX-Xyotax) and Concurrent Radiation for Esophageal and Gastric Cancer: A Phase I Study

  2006cited by this paper
• NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent

  2006cited by this paper
• Novel agents that target tublin and related elements.

  2006influential reference
• Phase 1 Study of ABT-751, a Novel Microtubule Inhibitor, in Patients with Refractory Hematologic Malignancies

  2005cited by this paper
• Patupilone (epothilone B) inhibits growth and survival of multiple myeloma cells in vitro and in vivo.

  2005cited by this paper
• Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer.

  2005cited by this paper
• Patupilone (epothilone B, EPO906) and imatinib (STI571, Glivec) in combination display enhanced antitumour activity in vivo against experimental rat C6 glioma

  2005cited by this paper
• Phase I study of the novel taxane CT-2103 in patients with advanced solid tumors

  2005cited by this paper
• Tubulin assembly, taxoid site binding, and cellular effects of the microtubule-stabilizing agent dictyostatin.

  2005cited by this paper
• Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111.

  2005cited by this paper
• Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies.

  2005cited by this paper
• The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth

  2005cited by this paper
• Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer.

  2005cited by this paper
• Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer.

  2005cited by this paper
• Paclitaxel poliglumex (PPX) in combination with carboplatin (carb) for the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC): Preliminary data

  2005cited by this paper
• Phase 1 and pharmacokinetic (PK) study of weekly KOS-862 (Epothilone D) combined with gemcitabine (GEM) in patients (Pts) with advanced solid tumors

  2005cited by this paper
• ILX651 administered daily for five days every 3 weeks (qdx5dq3w) in patients (pts) with inoperable locally advanced or metastatic melanoma: Phase II experience

  2005cited by this paper
• Phase II trial of KOS-862 (epothilone D) in anthracycline and taxane pretreated metastatic breast cancer

  2005cited by this paper
• Phase 1 trial of KOS-862 (epothilone D) in combination with carboplatin (C) in patients with solid tumors

  2005cited by this paper
• A phase I pharmacokinetic (PK) trial of XAA296A (Discodermolide) administered every 3 wks to adult patients with advanced solid malignancies.

  2004cited by this paper
• Preclinical pharmacological profile of ABJ879, a novel epothilone B analog with potent and protracted anti-tumor activity

  2004cited by this paper
• Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.

  2004cited by this paper
• Phase I Clinical and Pharmacokinetic Study of BMS-247550, a Novel Derivative of Epothilone B, in Solid Tumors

  2004cited by this paper
• Epothilones: mechanism of action and biologic activity.

  2004cited by this paper
• A multicenter phase II study of the cryptophycin analog LY355703 in patients with platinum-resistant ovarian cancer

  2004cited by this paper
• Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days.

  2003cited by this paper
• BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy.

  2001cited by this paper
• The coral-derived natural products eleutherobin and sarcodictyins A and B: effects on the assembly of purified tubulin with and without microtubule-associated proteins and binding at the polymer taxoid site.

  1999cited by this paper
• Localization of the vinblastine-binding site on beta-tubulin.

  1996cited by this paper
• Epothilons A and B: antifungal and cytotoxic compounds from Sorangium cellulosum (Myxobacteria). Production, physico-chemical and biological properties.

  1996cited by this paper
• Epothilons A and B: Antifungal and Cytotoxic Compounds from Sorangium cellulosum (Myxobacteria). Production, Physico-chemical and Biological Properties.:Production, Physico-chemical and Biological Properties

  1996cited by this paper
• Localization of the Vinblastine-binding Site on β-Tubulin*

  1996cited by this paper
• Combined antimicrotubule activity of estramustine and taxol in human prostatic carcinoma cell lines.

  1992cited by this paper
• Microtubule dynamics: mechanism, regulation, and function.

  1991cited by this paper

• From Motor Proteins to Oncogenic Factors: The Evolving Role of Kinesin Superfamily Proteins in Breast Cancer Development.

  2025cites this paper
• Herbal Therapies for Cancer Treatment: A Review of Phytotherapeutic Efficacy

  2024cites this paper
• In Silico Exploration of Microtubule Agent Griseofulvin and Its Derivatives Interactions with Different Human β-Tubulin Isotypes

  2023cites this paper
• Vinorelbine-related tetraplegia due to severe peripheral neuropathy

  2023cites this paper
• Comparative Evaluation of Two Paclitaxel-Coated Stents in an Experimental Setting

  2023cites this paper
• Anti‐tumor and cardiotoxic effects of microtubule polymerization inhibitors: The mechanisms and management strategies

  2023cites this paper
• Spectrin: an alternate target for cytoskeletal drugs

  2022cites this paper
• Knockout of DROSHA Increases the Sensitivity of HCT116 Cells to Apoptosis in Response to Actinomycin-D Treatment

  2022cites this paper
• A novel docetaxel derivative exhibiting potent anti-tumor activity and high safety in preclinical animal models.

  2022cites this paper
• Taccalonolides: Structure, semi-synthesis, and biological activity

  2022cites this paper
• Identification and validation of an inflammation-related lncRNAs signature for improving outcomes of patients in colorectal cancer

  2022cites this paper
• A Critical Analysis of Drugs Used in Anticancer Therapy Isolated from the Catharanthus roseus : A Review

  2022cites this paper
• The impact of SBF2 on taxane-induced peripheral neuropathy

  2022cites this paper
• Exploring the structural and functional requirements of Phyto-compounds and their synthetic scaffolds as anticancer agents: medicinal chemistry perspective

  2022cites this paper
• Synthesis, anticancer activity and molecular docking studies of N-deacetylthiocolchicine and 4-iodo-N-deacetylthiocolchicine derivatives.

  2021cites this paper
• Marine Antitumor Peptide Dolastatin 10: Biological Activity, Structural Modification and Synthetic Chemistry

  2021cites this paper
• Drug-Induced Peripheral Neuropathy: Diagnosis and Management.

  2021cites this paper
• Computational Prediction and Experimental Validation of the Unique Molecular Mode of Action of Scoulerine

  2021cites this paper
• cGAS-STING Signaling Pathway and Liver Disease: From Basic Research to Clinical Practice

  2021cites this paper
• Discovery of dihydrofuranoallocolchicinoids - Highly potent antimitotic agents with low acute toxicity.

  2020cites this paper
• SYTL4 downregulates microtubule stability and confers paclitaxel resistance in triple-negative breast cancer

  2020cites this paper
• Artemisia annua herbal preparations – Antitumor activity, analytical characterization, and identification of potential anticancer ingredients

  2020cites this paper
• Pan Aurora Kinase Inhibitor: A Promising Targeted-Therapy in Dedifferentiated Liposarcomas With Differential Efficiency Depending on Sarcoma Molecular Profile

  2020cites this paper
• Tumor-targeted drug delivery by nanocomposites.

  2020cites this paper
• PLANTS- DERIVED MATERIALS AND THEIR EFFECTS AS ANTICANCER AGENTS: A REVIEW

  2020cites this paper
• Exploring near-infrared absorbing nanocarriers to overcome cancer drug resistance

  2020influential citation
• Microtubule cytoskeleton-disrupting activity of MWCNTs: applications in cancer treatment

  2020cites this paper
• Structure-activity relationships, biological evaluation and structural studies of novel pyrrolonaphthoxazepines as antitumor agents.

  2019cites this paper
• University of Birmingham A perspective on polo-like kinase-1 inhibition for the treatment of rhabdomyosarcoma

  2019cites this paper
• Deoxypodophyllotoxin Exerts Anti-Cancer Effects on Colorectal Cancer Cells Through Induction of Apoptosis and Suppression of Tumorigenesis

  2019cites this paper
• Cink4T, a quinazolinone-based dual inhibitor of Cdk4 and tubulin polymerization, identified via ligand-based virtual screening, for efficient anticancer therapy.

  2019cites this paper
• Pharmacokinetics of a novel microtubule inhibitor mHA11 in rats.

  2019cites this paper
• A Perspective on Polo-Like Kinase-1 Inhibition for the Treatment of Rhabdomyosarcomas

  2019cites this paper
• Basic principles of drug delivery systems - the case of paclitaxel.

  2019cites this paper
• Colchicine Binding Site Agent DJ95 Overcomes Drug Resistance and Exhibits Antitumor Efficacy

  2019cites this paper
• Antitumor activity of an Artemisia annua herbal preparation and identification of active ingredients.

  2019cites this paper
• Pocket similarity identifies selective estrogen receptor modulators as microtubule modulators at the taxane site

  2019cites this paper
• Anticancer Molecules from Catharanthus roseus

  2019cites this paper
• Targeting the CINful genome: Strategies to overcome tumor heterogeneity.

  2019cites this paper
• Knockdown of LncRNA MAPT-AS1 inhibites proliferation and migration and sensitizes cancer cells to paclitaxel by regulating MAPT expression in ER-negative breast cancers

  2018cites this paper
• In vitro assessment of chemotherapy-induced neuronal toxicity.

  2018cites this paper
• Characteristics, Properties and Analytical Methods of Paclitaxel: A Review

  2018cites this paper
• Chemotherapeutic agents for the treatment of metastatic breast cancer: An update.

  2018cites this paper
• Identification of mechanisms of acquired resistance to taxanes in triple negative breast cancer using patient-derived xenografts: a step closer to clinics

  2018cites this paper
• Adding Pertuzumab to Trastuzumab and Taxanes in HER2 positive breast cancer

  2018cites this paper
• A Critical Review of Properties and Analytical Methods for the Determination of Docetaxel in Biological and Pharmaceutical Matrices

  2018cites this paper
• Interactions of long-chain homologues of colchicine with tubulin.

  2017cites this paper
• Importancia de la temperatura de la quimioterapia intraperitoneal intraoperatoria con paclitaxel en el tratamiento quirúrgico radical de la carcinomatosis peritoneal de origen ovárico. Hipertermia versus normotermia

  2017cites this paper
• Cancer Tissue Classification, Associated Therapeutic Implications and PDT as an Alternative.

  2017cites this paper
• Microtubule inhibitor, SP-6-27 inhibits angiogenesis and induces apoptosis in ovarian cancer cells

  2017cites this paper
• A Critical Review of Properties and Analytical Methods for the Determination of Oxytetracyline in Biological and Pharmaceutical Matrices

  2017cites this paper
• Dynamics of Mitotic Microtubules in Fission Yeast

  2017cites this paper
• Taxotere as a Treatment for Ovarian Epithelial Carcinoma

  2017cites this paper
• Utilization of iPSC-derived human neurons for high-throughput drug-induced peripheral neuropathy screening.

  2017cites this paper
• The gamma-tubulin meshwork as a therapeutic target

  2017cites this paper
• The pretubulysin-induced exposure of collagen is caused by endothelial cell retraction that results in an increased adhesion and decreased transmigration of tumor cells

  2017cites this paper
• Synthesis and biological evaluation of simplified pironetin analogues with modifications in the side chain and the lactone ring.

  2016cites this paper
• Chapter 2 – Introduction to Systemic Antineoplastic Treatments for Cardiologists

  2016cites this paper
• Synthesis and Cytotoxicity of Two Active Metabolites of Larotaxel.

  2016cites this paper
• MLN-8237: A dual inhibitor of aurora A and B in soft tissue sarcomas

  2016cites this paper
• A phase I study of BI 811283, an Aurora B kinase inhibitor, in patients with advanced solid tumors

  2016cites this paper
• Determination of 6258-70, a new semi-synthetic taxane, in rat plasma and tissues: Application to the pharmacokinetics and tissue distribution study☆

  2016cites this paper
• Nab-Paclitaxel in Metastatic Breast Cancer: Defining the Best Patient Profile.

  2016cites this paper
• Current Advances of Tubulin Inhibitors in Nanoparticle Drug Delivery and Vascular Disruption/Angiogenesis

  2016cites this paper
• FTIR spectral signature of anticancer drugs. Can drug mode of action be identified?

  2016cites this paper
• Pharmacogenomics of second-line drugs used for treatment of unresponsive or relapsed osteosarcoma patients.

  2016cites this paper
• Analysis of initial efficacy results of a new cytotoxic prodrug, CAP7.1, in adults with therapy refractory solid tumours in a phase I clinical trial

  2016cites this paper
• Axonal Transport Impairment in Chemotherapy-Induced Peripheral Neuropathy

  2015cites this paper
• Clinical Trials of Mitotic Kinesin Inhibitors

  2015cites this paper
• Eribulin for the treatment of metastatic breast cancer: an update on its safety and efficacy

  2015cites this paper
• ResearchCurcumin induces chemo / radio-sensitization in ovarian cancer cells and curcumin nanoparticles inhibit ovarian cancer cell growth

  2015cites this paper
• Drug Targets for Cancer Treatment: An Overview

  2015cites this paper
• IPP51, a chalcone acting as a microtubule inhibitor with in vivo antitumor activity against bladder carcinoma

  2015cites this paper
• Septin cooperation with tubulin polyglutamylation contributes to cancer cell adaptation to taxanes

  2015cites this paper
• In vitro and in vivo conditional sensitization of hepatocellular carcinoma cells to TNF-induced apoptosis by Taxol

  2015cites this paper
• Advances of Microtubule-Targeting Small Molecular Anticancer Agents from Marine Origin

  2015cites this paper
• First-in-human phase 1 study of filanesib (ARRY-520), a kinesin spindle protein inhibitor, in patients with advanced solid tumors

  2015cites this paper
• Characterisation of CTR-17 and CTR-20, novel chalcone derivatives that inhibit tubulin polymerisation activity

  2015cites this paper
• Biological characterisation of a novel and naturally isolated indole alkaloid

  2015cites this paper
• Anticancer compounds from Philippine marine organisms act on major pathways in cancer

  2014cites this paper
• An in vitro study of the mechanisms that underlie changes in neuronal sensitivity and neurite morphology following treatment with microtubule targeting agents

  2014cites this paper
• Class III beta-tubulin, drug resistance and therapeutic approaches in cancers

  2014influential citation
• Design, Synthesis and Bioevaluation of an EphA2 Receptor‐Based Targeted Delivery System

  2014cites this paper
• Small molecule modulators of protein-protein interactions: selected case studies.

  2014cites this paper
• Cardiotoxic Changes of Colchicine Intoxication in Rats: Electrocardiographic, Histopathological and Blood Chemical Analysis

  2014cites this paper
• Ixabepilone-induced mitochondria and sensory axon loss in breast cancer patients

  2014cites this paper
• Recent developments in tubulin polymerization inhibitors: An overview.

  2014cites this paper
• Novel third-generation water-soluble noscapine analogs as superior microtubule-interfering agents with enhanced antiproliferative activity.

  2014cites this paper
• Profile and potential of ixabepilone in the treatment of pancreatic cancer

  2014influential citation
• Synthesis and Characterization of Biodegradable Amphiphilic Star and Y-Shaped Block Copolymers as Potential Carriers for Vinorelbine

  2014cites this paper
• Lipid quantification method using FTIR spectroscopy applied on cancer cell extracts.

  2014cites this paper
• Tubulin inhibitors: a patent review

  2014cites this paper
• Predictive impact of RRM1 protein expression on vinorelbine efficacy in NSCLC patients randomly assigned in a chemotherapy phase III trial.

  2013cites this paper
• Treatment of neuroblastoma and rhabdomyosarcoma using RGD-modified liposomal formulations of patupilone (EPO906)

  2013cites this paper
• Biology‐Oriented Synthesis of a Tetrahydroisoquinoline‐Based Compound Collection Targeting Microtubule Polymerization

  2013cites this paper
• Reversible Action of Diaminothiazoles in Cancer Cells Is Implicated by the Induction of a Fast Conformational Change of Tubulin and Suppression of Microtubule Dynamics

  2013cites this paper
• Regulation of microtubule-associated protein tau (MAPT) by miR-34c-5p determines the chemosensitivity of gastric cancer to paclitaxel

  2013cites this paper
• Histopathological studies of microtubule disassembling agent-induced myocardial lesions in rats.

  2013cites this paper
• Oncogenic role of kinesin proteins and targeting kinesin therapy

  2013cites this paper
• Eribulin Mesylate in Breast Cancer

  2013cites this paper